- Home
- ETON vs CMRX Comparison
ETON vs CMRX Comparison
Compare ETON & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- CMRX
- Stock Information
- Founded
- ETON 2017
- CMRX 2000
- Country
- ETON United States
- CMRX United States
- Employees
- ETON N/A
- CMRX N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- CMRX Health Care
- Exchange
- ETON Nasdaq
- CMRX Nasdaq
- Market Cap
- ETON 199.5M
- CMRX 77.0M
- IPO Year
- ETON 2018
- CMRX 2013
- Fundamental
- Price
- ETON $8.82
- CMRX $0.93
- Analyst Decision
- ETON Strong Buy
- CMRX Strong Buy
- Analyst Count
- ETON 3
- CMRX 1
- Target Price
- ETON $12.00
- CMRX $11.00
- AVG Volume (30 Days)
- ETON 214.1K
- CMRX 119.4K
- Earning Date
- ETON 11-11-2024
- CMRX 11-08-2024
- Dividend Yield
- ETON N/A
- CMRX N/A
- EPS Growth
- ETON N/A
- CMRX N/A
- EPS
- ETON N/A
- CMRX N/A
- Revenue
- ETON $31,381,000.00
- CMRX $144,000.00
- Revenue This Year
- ETON $19.61
- CMRX $3,040.12
- Revenue Next Year
- ETON $35.39
- CMRX N/A
- P/E Ratio
- ETON N/A
- CMRX N/A
- Revenue Growth
- ETON 8.14
- CMRX N/A
- 52 Week Low
- ETON $3.03
- CMRX $0.75
- 52 Week High
- ETON $8.66
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- CMRX 60.78
- Support Level
- ETON $7.58
- CMRX $0.80
- Resistance Level
- ETON $8.66
- CMRX $0.98
- Average True Range (ATR)
- ETON 0.42
- CMRX 0.05
- MACD
- ETON -0.07
- CMRX 0.01
- Stochastic Oscillator
- ETON 91.49
- CMRX 83.33
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.